Published in Proc Natl Acad Sci U S A on August 05, 2004
Simian immunodeficiency virus SIVmac239 infection of major histocompatibility complex-identical cynomolgus macaques from Mauritius. J Virol (2006) 2.38
Immunology and the elusive AIDS vaccine. Nature (2010) 2.26
Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol (2008) 1.74
Myd88 is required for an antibody response to retroviral infection. PLoS Pathog (2009) 1.35
Toll-like receptor 7 controls the anti-retroviral germinal center response. PLoS Pathog (2011) 1.16
B lymphocyte activation by coinfection prevents immune control of friend virus infection. J Immunol (2008) 1.06
Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response. PLoS Pathog (2011) 1.05
Effects of acute and chronic murine norovirus infections on immune responses and recovery from Friend retrovirus infection. J Virol (2009) 1.04
Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in friend virus-infected mice. J Virol (2010) 1.04
Elimination of friend retrovirus in the absence of CD8+ T cells. J Virol (2013) 0.93
Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology (2011) 0.90
Humoral immunity in the Friend retrovirus infection model. Immunol Res (2013) 0.87
Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia. Blood (2006) 0.86
Interleukin-encoding adenoviral vectors as genetic adjuvant for vaccination against retroviral infection. PLoS One (2013) 0.84
Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs. PLoS Pathog (2010) 0.84
Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment. J Virol (2005) 0.82
Fv1 restriction and retrovirus vaccine immunity in Apobec3-deficient 129P2 mice. PLoS One (2013) 0.79
Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: A novel tool for mechanistic and therapeutic studies. Cancer Lett (2012) 0.79
Retroviral immunology: lessons from a mouse model. Immunol Res (2009) 0.78
Induction of complex immune responses and strong protection against retrovirus challenge by adenovirus-based immunization depends on the order of vaccine delivery. Retrovirology (2017) 0.76
Antibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2. PLoS One (2015) 0.76
Filariae-Retrovirus Co-infection in Mice is Associated with Suppressed Virus-Specific IgG Immune Response and Higher Viral Loads. PLoS Negl Trop Dis (2016) 0.75
B Cell Requirement for Robust Regulatory T Cell Responses to Friend Retrovirus Infection. MBio (2017) 0.75
Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol (2003) 15.51
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature (1991) 13.19
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49
The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (1993) 11.15
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol (2001) 8.64
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 7.48
Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med (1996) 7.08
HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature (1998) 6.94
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med (1999) 6.91
Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 6.57
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science (1995) 6.30
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med (1999) 3.86
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol (2004) 3.58
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS (1999) 3.57
Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity (2004) 3.10
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A (1997) 3.02
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A (2001) 2.96
Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity (1998) 2.95
Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol (2000) 2.65
B-tropic Friend virus: a host-range pseudotype of spleen focus-forming virus (SFFV). Virology (1973) 2.34
Synthesis and glycosylation of polyprotein precursors to the internal core proteins of Friend murine leukemia virus. J Virol (1977) 2.26
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol (2001) 2.16
B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med (2000) 2.02
Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods (1991) 2.01
A critical role for B cells in the development of memory CD4 cells. J Immunol (2000) 1.97
Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A (2003) 1.88
Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol (1998) 1.83
Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat Med (1999) 1.74
Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol (2003) 1.70
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol (2002) 1.44
Different H-2 subregions influence immunization against retrovirus and immunosuppression. Nature (1987) 1.43
Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms. J Virol (1998) 1.39
Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol (1983) 1.38
Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J Virol (1993) 1.36
Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. Proc Natl Acad Sci U S A (1995) 1.33
Lymphocyte deficiencies increase susceptibility to friend virus-induced erythroleukemia in Fv-2 genetically resistant mice. J Virol (1999) 1.32
FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens. J Exp Med (1989) 1.25
HIV-1: nature's master of disguise. Nat Med (2003) 1.24
Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin Infect Dis (2001) 1.21
Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol (2003) 1.19
Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus. J Virol (1999) 1.18
Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain. J Virol (2000) 1.13
The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science (1990) 1.13
Steering a course to an AIDS vaccine. Science (2002) 1.12
Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells. AIDS Res Hum Retroviruses (2004) 1.10
HIV-1 neutralizing antibodies: how full is the bottle? Nat Med (1999) 1.09
Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol (2002) 1.01
Protection against establishment of retroviral persistence by vaccination with a live attenuated virus. J Virol (1999) 1.00
Synergy between an antibody and CD8+ cells in eliminating an established tumor. Eur J Immunol (1997) 0.98
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (2000) 0.92
N-terminal cleavage fragment of glycosylated Gag is incorporated into murine oncornavirus particles. J Virol (2001) 0.90
Different immunological requirements for protection against acute versus persistent Friend retrovirus infections. Virology (2000) 0.90
Phagocytic efficiency of monocytes and macrophages obtained from Sydney blood bank cohort members infected with an attenuated strain of HIV-1. J Acquir Immune Defic Syndr (2003) 0.84
Requirement for CD4(+) T cells in the Friend murine retrovirus neutralizing antibody response: evidence for functional T cells in genetic low-recovery mice. J Virol (1998) 0.84
The participation of B cells and antibodies in the selection and maintenance of T cell repertoires. Immunol Rev (1988) 0.82
Influence of infectious virus on the induction of transplantation resistance in the Friend tumor system. Cancer Res (1967) 0.78
Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis (2013) 4.87
Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity (2004) 3.10
HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med (2014) 2.39
The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol (2013) 2.10
Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science (2008) 1.97
Natural regulatory T cells and persistent viral infection. J Virol (2007) 1.62
Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology (2007) 1.59
Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology (2009) 1.59
BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection. Blood (2013) 1.57
Kinetics of CD8+ effector T cell responses and induced CD4+ regulatory T cell responses during Friend retrovirus infection. Eur J Immunol (2006) 1.56
Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J Virol (2007) 1.50
Evolution of raltegravir resistance during therapy. J Antimicrob Chemother (2009) 1.33
In vitro suppression of CD8+ T cell function by Friend virus-induced regulatory T cells. J Immunol (2006) 1.30
Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response. Cell Rep (2013) 1.28
Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points. Proc Natl Acad Sci U S A (2011) 1.26
CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection. J Virol (2005) 1.26
Regulatory T cells suppress antiviral immune responses and increase viral loads during acute infection with a lymphotropic retrovirus. PLoS Pathog (2009) 1.26
Immune control and prevention of chronic Friend retrovirus infection. Front Biosci (2007) 1.23
Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J Immunol (2011) 1.23
Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology (2009) 1.21
Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: comparison of multiple TLR7 and/or TLR8 agonists. J Immunol (2008) 1.20
Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog (2013) 1.16
Effects of type I interferons on Friend retrovirus infection. J Virol (2006) 1.14
The level of friend retrovirus replication determines the cytolytic pathway of CD8+ T-cell-mediated pathogen control. J Virol (2007) 1.10
The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3. J Virol (2010) 1.09
Lactate dehydrogenase-elevating virus induces systemic lymphocyte activation via TLR7-dependent IFNalpha responses by plasmacytoid dendritic cells. PLoS One (2009) 1.08
Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads. PLoS Pathog (2013) 1.08
Activation of the innate signaling molecule MAVS by bunyavirus infection upregulates the adaptor protein SARM1, leading to neuronal death. Immunity (2013) 1.07
Independent roles of perforin, granzymes, and Fas in the control of Friend retrovirus infection. Virology (2004) 1.07
Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia. Glia (2010) 1.06
A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathog (2012) 1.06
Allogeneic lymphocytes persist and traffic in feral MHC-matched mauritian cynomolgus macaques. PLoS One (2008) 1.05
CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells. J Immunol (2008) 1.05
Essential roles for CD8+ T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression. J Virol (2002) 1.05
The role of virus-induced regulatory T cells in immunopathology. Springer Semin Immunopathol (2006) 1.05
Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response. PLoS Pathog (2011) 1.05
Effects of acute and chronic murine norovirus infections on immune responses and recovery from Friend retrovirus infection. J Virol (2009) 1.04
Tissue-specific abundance of regulatory T cells correlates with CD8+ T cell dysfunction and chronic retrovirus loads. J Immunol (2009) 1.04
CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells. J Virol (2013) 1.03
Analysis of protein levels of 24 cytokines in scrapie agent-infected brain and glial cell cultures from mice differing in prion protein expression levels. J Virol (2009) 1.03
Temporal effects of gamma interferon deficiency on the course of Friend retrovirus infection in mice. J Virol (2002) 1.01
Reduction of retrovirus-induced immunosuppression by in vivo modulation of T cells during acute infection. J Virol (2004) 0.99
Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J Immunol (2010) 0.99
Silencing T cells or T-cell silencing: concepts in virus-induced immunosuppression. J Gen Virol (2006) 0.97
Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection. PLoS Pathog (2012) 0.97
Toll-like receptor 7 is not necessary for retroviral neuropathogenesis but does contribute to virus-induced neuroinflammation. J Neurovirol (2008) 0.95
Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC Immunol (2008) 0.95
Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia. J Virol (2003) 0.95
Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide. J Virol (2007) 0.95
CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem (2004) 0.94
Neuropeptide Y has a protective role during murine retrovirus-induced neurological disease. J Virol (2010) 0.94
Infection of cardiomyocytes and induction of left ventricle dysfunction by neurovirulent polytropic murine retrovirus. J Virol (2007) 0.93
Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor. J Virol (2010) 0.93
Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naive T cells, and favors expansion of regulatory T cells. Blood (2007) 0.92
Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J Virol (2010) 0.91
Mechanisms of control of acute Friend virus infection by CD4+ T helper cells and their functional impairment by regulatory T cells. J Gen Virol (2009) 0.91
TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS. Am J Pathol (2011) 0.91
Differential impact of the transcriptional repressor Gfi1 on mature CD4+ and CD8+ T lymphocyte function. Eur J Immunol (2007) 0.91
Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies. Vaccine (2007) 0.90
Anti-retroviral effects of type I IFN subtypes in vivo. Eur J Immunol (2009) 0.90
IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3. J Immunol (2013) 0.90
Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology (2011) 0.90
Distinct roles of CD4+ T cell subpopulations in retroviral immunity: lessons from the Friend virus mouse model. Retrovirology (2011) 0.89
Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro. Int Immunol (2013) 0.89
The phenotype and activation status of regulatory T cells during Friend retrovirus infection. Virol Sin (2014) 0.88
Distinct roles of NK cells in viral immunity during different phases of acute Friend retrovirus infection. Retrovirology (2013) 0.88
Polyinosinic-polycytidylic acid treatment of Friend retrovirus-infected mice improves functional properties of virus-specific T cells and prevents virus-induced disease. J Immunol (2010) 0.87
Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol (2002) 0.87
IL-2-independent and TNF-α-dependent expansion of Vβ5+ natural regulatory T cells during retrovirus infection. J Immunol (2013) 0.86
Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection. J Virol (2011) 0.86
TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8+ T cell immunity in vitro. J Immunol (2013) 0.86
Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc Natl Acad Sci U S A (2013) 0.85
Negative impact of IFN-γ on early host immune responses to retroviral infection. J Immunol (2012) 0.85
Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs. PLoS Pathog (2010) 0.84
Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells. Cancer Immunol Immunother (2012) 0.84
Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opin Drug Discov (2012) 0.84
Complement opsonization enhances friend virus infection of B cells and thereby amplifies the virus-specific CD8+ T cell response. J Virol (2010) 0.83
Development of genetic system to inactivate a Borrelia turicatae surface protein selectively produced within the salivary glands of the arthropod vector. PLoS Negl Trop Dis (2013) 0.83
NK cells improve control of friend virus infection in mice persistently infected with murine cytomegalovirus. Retrovirology (2013) 0.83
CD8+ T cells are essential for controlling acute friend retrovirus infection in C57BL/6 mice. J Virol (2014) 0.82